TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype
| Autor: | Yanling Ren, Shuanghong Zhu, Jie Jin, Hua Zhang, Lingxu Jiang, Yingwan Luo, Hongyan Tong, Li Ye, Xinping Zhou, Jinghan Wang, Chen Mei, Lu Wang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Poor prognosis medicine.medical_specialty Monosomy 5 Decitabine Gene mutation Tp53 mutation Gastroenterology 03 medical and health sciences 0302 clinical medicine Monosomy Internal medicine Complex Karyotype Medicine Humans 030212 general & internal medicine Aged Retrospective Studies business.industry Retrospective cohort study General Medicine Middle Aged Prognosis Oncology 030220 oncology & carcinogenesis Karyotyping Myelodysplastic Syndromes Mutation Female Tumor Suppressor Protein p53 business Monosomal karyotype medicine.drug |
| Zdroj: | Asia-Pacific journal of clinical oncologyREFERENCES. 16(3) |
| ISSN: | 1743-7563 |
| Popis: | AIM The aim of this study was to evaluate the clinical and molecular characteristics of myelodysplastic syndrome (MDS) patients with monosomal karyotype (MK). METHODS Eighty MDS patients with MK diagnosed between January 2010 and December 2018 were included in the retrospective study. Seventy-three had complex karyotype (CK) and 46 had very CK (vCK, ≥ 5 abnormalities). Clinical information was collected, and a panel of 37 genes, on which mutations have been previously reported to be associated with MDS patients, was analyzed by next-generation sequencing. Genetic and biological features and their association with survival were evaluated. RESULTS Monosomy 5, 7, and 17 were the most frequent and mainly occurred in patients with vCK. While median overall survival (OS) for all patients was 12.8 months with 95% CI 9.1-16.5, patients with vCK had shorter OS (8.4 months with 95% CI 3.9-12.8) than those with non-vCK (16.1 months with 95% CI 11.5-20.8) (P = .02). At least one gene mutation was detected in 76 patients (95%), TP53 mutations were detected in 57 patients, and their median OS was significantly shorter than those without TP53 mutations (9.5 months with 95% CI 7.5-11.5 vs 26.1 months with 95% CI 8.0-44.2, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text